WE WILL Deliver on Our Future
28 FEB 2023
The start of each year brings with it our annual Kick Start meeting – a time to celebrate the previous year’s successes, align on our priorities, and ensure our readiness for the future.
We did a lot over two fast-paced days, sharing what we’ve done, why we’re doing it, and how we execute on those programs. And we walked away knowing what’s needed for EMD Serono’s success in 2023 and beyond. We have a fantastic future ahead, focused on our high-impact culture to deliver on our strategic priorities.
The central message echoed throughout the meeting was that WE WILL reach our aspiration and future goals. As a positive, caring, passionate, pioneering company, we know we have a strong legacy across our core portfolio. We have made important contributions to patients impacted by infertility, HIV, cancer and MS thanks to our engagement, teamwork and cooperation.
Looking ahead, we want to build on that foundation, raising the bar to address unmet medical needs in our areas of leadership. By focusing on our strengths, we can think big and innovate boldly to impact lives. We have incredible opportunity ahead of us, including through our Phase III assets, evobrutinib and xevinapant, which have the potential to drive our next wave of launches.
These innovative compounds have the potential to address critical unmet needs. And as the US healthcare business of Merck KGaA, Darmstadt, Germany, EMD Serono’s role in delivering these therapies to patients across the US is critical to our global strategy.
To succeed, we have set high bars to double R&D productivity and bring more medicines to more patients, faster. We aspire to introduce one new product/indication every ~1.5 years that brings meaningful value to patients. And we intend to accomplish this by harnessing our expertise within the existing pipeline, while augmenting that innovation with increased external collaboration.
We have an exciting double mission ahead that requires us to keep the momentum going with our core business while we progress development of evobrutinib and xevinapant. But if we continue to operate as one team, laser-focused on areas that drive high impact, I have every expectation that we’ll succeed.
EMD Serono is a terrific company, and we’re on the cusp of a wave of innovation that will help us continue to deliver on our quest to help create, improve and prolong lives.